PSA testing remains the only biomarker for prostate cancer detection and monitoring, but its specificity and sensitivity are limited, often leading to misdiagnosis as prostatitis or prostate stones (Benchikh El Fegoun and Villers, 2007). This evidence concerns the gene KLK3 and prostate carcinoma.